RxDoctor Payments Data

Lawrence Bluth, MD

Neurology · Hartford, CTNPI 1699785469

Payments from drug & device makers

$15,488in general payments, 2019–2025

Across 1,042 payments — averaging $14.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$1K
  • Pfizer$1K
  • EMD Serono, Inc.$688
  • AstraZeneca$688
  • Amgen$665
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$1691%
  • Food & beverage$15,31999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)149$1,924
Novartis125$1,481
Pfizer89$1,039
EMD Serono, Inc.55$688
AstraZeneca(2 entities)25$688
Amgen(2 entities)41$665
UCB, Inc.39$643
Sanofi33$619
SK Life Science, Inc.38$598
TG Therapeutics, Inc.23$591
Biogen45$535
Bristol Myers Squibb33$425
Teva Pharmaceuticals USA, Inc.41$337
Amneal Pharmaceuticals LLC24$323
Acorda Therapeutics, Inc14$278
Kyowa Kirin, Inc.21$278
Lundbeck LLC14$264
Biohaven Pharmaceutical Holding Company Ltd.26$211
MDD US Operations, LLC15$202
Takeda Pharmaceuticals U.S.A., Inc.10$200
Eisai Inc.10$199
Argenx US, Inc.6$188
Genentech USA, Inc.8$181
Tanabe Pharma America, Inc.8$170
Neurocrine Biosciences, Inc.4$167
Acadia Pharmaceuticals Inc15$166
Akcea Therapeutics, Inc.3$157
Supernus Pharmaceuticals, Inc.11$154
Octapharma USA, Inc.6$148
Grifols USA, LLC7$137
GE HealthCare8$130
Sunovion Pharmaceuticals Inc.8$123
Biohaven Pharmaceuticals, Inc.14$119
Johnson & Johnson5$110
Arbor Pharmaceuticals, Inc.5$109
Xeris Pharmaceuticals, Inc.5$92
Cycle Pharmaceuticals Inc4$84
Adamas Pharmaceuticals, Inc.5$83
Axsome Therapeutics, Inc.4$74
Abbott4$73
Catalyst Pharmaceuticals, Inc.3$70
Avanir Pharmaceuticals, Inc.4$67
Lilly USA, LLC3$65
Amylyx Pharmaceuticals, Inc.3$62
Vanda Pharmaceuticals Inc.2$53
Alnylam Pharmaceuticals Inc.3$53
Upsher-smith Laboratories LLC3$52
Baxter Healthcare2$37
Neurelis, Inc.1$37
Strongbridge US Inc.3$37
Collegium Pharmaceutical, Inc.2$36
Kedrion Biopharma, Inc.2$34
Mallinckrodt Hospital Products Inc.1$31
GSK1$28
Avion Pharmaceuticals2$27
Mallinckrodt Enterprises LLC1$26
Insightec,inc1$25
Vertical Pharmaceuticals, LLC1$24
CSL Behring1$22
Invivyd Inc1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,488 in reported general payments places this provider in the 70th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$144,598
Medicare patients
428
Services billed
941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5024$293,567
AubagioTeriflunomide12$107,996
Kesimpta PenOfatumumab12$97,421
Teriflunomide12$50,350
Nurtec OdtRimegepant Sulfate29$39,531
NourianzIstradefylline19$37,123
NeuproRotigotine21$29,550
Aimovig AutoinjectorErenumab-Aooe12$27,339
Tegretol XrCarbamazepine39$21,379
AptiomEslicarbazepine Acetate12$17,708
Carbidopa-LevodopaCarbidopa/Levodopa417$14,787
Gabapentin467$13,613
Oxcarbazepine33$10,675
Levetiracetam321$8,896
Depakote ErDivalproex Sodium13$8,757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$22$293,56724 claims
SanofiAubagio$619$107,99612 claims
PfizerNurtec Odt, Dilantin$1,039$44,23040 claims
Kyowa Kirin, Inc.Nourianz$278$37,12319 claims
UCB, Inc.Neupro$643$29,55021 claims
Sunovion Pharmaceuticals Inc.Aptiom$123$17,70812 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$323$3,13638 claims
Upsher-smith Laboratories LLCTopiramate$52$83162 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 280 neurology providers in Connecticut.

Other neurology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →